arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

NeuroPace Inc

NPCE
$13.97 ▼ -0.24 (-1.69%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
7 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

NeuroPace Inc faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $457.1M
Dividend Yield —
Revenue Growth 25.1% ↗
Op. Margin -16.3% ↗
ROIC -16.6% ↗
FCF / Share $-0.35 ↗
Trailing P/E —
Price / Book 24.7x
FCF Yield —
Debt / Equity 3.09
info Valuation on last close. End-of-day price, Sep 24, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$99.99M
↑ +25.1% —
Net Income Profit after all expenses
$-21.46M
↑ +20.9% —
Operating Margin Operating profit as % of sales
-16.3%
↑ +39.7% 11th
FCF / Share Free cash flow per share
$-0.35
↑ +44.7% —
Long-Term Debt Long-term obligations
$58.88M
↓ -1.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
11
Returns
7
Financial Health ↑
24
Cash Quality ↓
41

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 7 years · 27 quarters